Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-blind, Randomized, Placebo Controlled Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants

NCT07010822 is registered in ClinicalTrials.gov with Fidec Corporation as lead sponsor.

NCT NCT07010822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07010822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-blind, Randomized, Placebo Controlled Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants
Lead sponsor
Fidec Corporation
Phase
Phase 3
Overall status
Recruiting
Start date
April 30, 2026
Completion date
March 8, 2027
Enrollment
740 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

poliomyelitis